Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | MC4R | P32245 | 1/20 | 0.62 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.57 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | CHKA | P35790 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | PHGDH | O43175 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13535291 | 0.87 | MC4R (0.74) | MC4RSIGMAR1KDM4ECHKAHRH3 | |
| SCHEMBL9025487 | 0.84 | SMN1; SMN2 (0.96) | SMN1; SMN2TDP1MBTD1L3MBTL3SIGMAR1 | |
| SCHEMBL3641561 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2TDP1MBTD1L3MBTL3SIGMAR1 | |
| SCHEMBL6818314 | 0.82 | SMN1; SMN2 (0.93) | SMN1; SMN2TDP1MBTD1L3MBTL3SIGMAR1 | |
| SCHEMBL29197757 | 0.81 | SMN1; SMN2 (0.72) | SMN1; SMN2TDP1MBTD1L3MBTL3SIGMAR1 | |
| SCHEMBL10076573 | 0.81 | MC4R (0.65) | MC4RKDM4EFAAHHRH3LMNA | |
| SCHEMBL12830614 | 0.81 | MC4R (0.65) | TDP1MC4RSIGMAR1KDM4ECHKA | |
| SCHEMBL10671525 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2TDP1MC4RMBTD1L3MBTL3 | |
| SCHEMBL2634372 | 0.80 | SMN1; SMN2 (0.66) | SMN1; SMN2TDP1MBTD1L3MBTL3SIGMAR1 | |
| SCHEMBL28315093 | 0.80 | MBTD1 (0.67) | SMN1; SMN2TDP1MBTD1L3MBTL3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110194769-A | A kind of bis- target spot inhibitor of HDAC, CDK and the preparation method and application thereof | 重庆医科大学 | 2019-09-03 | — | — | CN | disclosed |
| US-8633173-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130296312-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8501936-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| CN-102459258-A | Preparation and use of 1,2, 4-triazolo [1,5a ] pyridine derivatives | CEPHALON INC | 2012-05-16 | — | — | CN | disclosed |
| EP-2438066-A2 | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES | Cephalon, Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-8067599-B2 | Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-7932247-B2 | M3 muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2011-04-26 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| WO-2009076602-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | WYETH (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149447-A1 | Novel M3 Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-06-11 | — | — | US | disclosed |
| EP-2064213-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2009-06-03 | — | — | EP | disclosed |
| US-7494993-B2 | Amide derivatives of 7-amino-3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| WO-2008028617-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-13 | — | — | WO | disclosed |
| US-20080032970-A1 | Amide Derivatives of 7-Amino-3-Phenyl-Dihydropyrimido[4,5-D]Pyrimidinones, Their Manufacture and Use as Pharmaceutical Agents | HOFFMANN-LA ROCHE INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2007134449-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2007-11-29 | — | — | WO | disclosed |
| CN-1984914-A | Amide derivatives of 7-amino-3-phenyl-dihydropyrimido [4, 5-d ] pyrimidinones, their preparation and use as protein kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2007-06-20 | — | — | CN | disclosed |
| EP-1789417-A1 | AMIDE DERIVATIVES OF 7-AMINO-3-PHENYL-DIHYDROPYRIMIDO [4,5-d]PYRIMIDINONES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006024487-A1 | AMIDE DERIVATIVES OF 7-AMINO-3-PHENYL-DIHYDROPYRIMIDO [4,5-d]PYRIMIDINONES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149447-A1 | Novel M3 Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRM2, CHRNA3 | SMN1; SMN2 3928/4885TDP1 3207/4885MC4R 388/4885 |
| US-20130296312-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | JAK2, JAK1, JAK3 | SMN1; SMN2 3360/4885TDP1 1611/4885MC4R 844/4885 |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | APP, BACE1, IAPP | SMN1; SMN2 2222/4885TDP1 1634/4885MC4R 3578/4885 |
| US-20080032970-A1 | Amide Derivatives of 7-Amino-3-Phenyl-Dihydropyrimido[4,5-D]Pyrimidinones, Their Manufacture and Use as Pharmaceutical Agents | DPYD, GART, DDC | SMN1; SMN2 3861/4885TDP1 2511/4885MC4R 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.